Organ-Sparing Treatment in Muscle-Invasive Bladder Cancer

Abstract

The data obtained in this study confirm the high efficacy of TUR and radiochemotherapy for locally advanced bladder cancer.

Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients

“…The 5-year survival rate in that study was 45%. When comparing the results of these previous studies including more intensive chemoradiation programs mainly for the primary treatment of muscle-invasive bladder cancer to the results of our present series, the results of the present study with a 5-year survival rate of 100% can be considered quite promising (6,11). Since the current study included only a very small number of patients, its findings need to be confirmed in a larger prospective trial.…”

“…In the previous study, 13 of 42 patients (31%) died, 7 patients (17%) due to bladder cancer (6) and 3 patients (7%) due to development of local recurrence. In another study of 68 patients receiving organpreserving treatment for primary muscle-invasive bladder cancer, 34 patients (50%) were treated with chemoradiation in vivo 31: 239-242 (2017) 240 (11). The 5-year survival rate in that study was 45%.…”

Long‐term follow up of patients with invasive bladder carcinoma receiving combined cisplatin‐based intra‐arterial chemotherapy and radiotherapy

“…Generally, a total dose of 60 Gy or higher is used , with concurrent chemotherapy, and these combined chemotherapies yield high response rates. 5,7,12 Our initial radiotherapy consisted of a 40-Gy dose followed by a 20-Gy boost. However, the boost radiotherapy was difficult to complete due to the side-effects and the requirement for a longer hospital stay.…”

Concurrent Radiotherapy and Taxane Chemotherapy in Patients with Locoregional Recurrence of Breast Cancer

“…• Cisplatin, a drug with a known radiosensitizing effect on other types of organ tumors [2,5,8,18,19,31], was also added to the chemotherapy protocol for patients with locally advanced tumors.…”

“…In recent years, certain drugs, in particular taxanes, were shown to be potent cytostatic agents for systemic treatment of breast cancer [1,23,29] as well as radiosensitizers for treatment of other tumor entities [8,18,19,31]. We have compiled the largest amount of data ever published regarding toxicity and efficacy with high-dose radiotherapy plus chemotherapy with a taxane alone (paclitaxel or docetaxel; TAX/RT) or in combination with cisplatin (paclitaxel plus cisplatin; TAX/CIS/RT) in recurrent breast cancer.…”